Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study is aimed to assess the efficacy of Human derived Transfer factor ( T-lymphocytes
homogenate that contains small molecular weight (10 kDa) molecules: various IFNs, ILs,
chemokines, endorfins, heat shock proteins) in decreasing rate and/or severity of infections
in acute or chronic decompensations of liver cirrhosis and acute on chronic liver failure..
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Martin Janičko
Collaborator:
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica